Controlled study of bromocriptine and placebo for induction of ovulation in normoprolactinemic secondary amenorrhea.
In order to evaluate the effect of bromocriptine in the treatment of secondary amenorrhea, a double-blind placebo-controlled study including 30 women with normo-prolactinemic normo-hypogonadotropic hypogonadism was carried out. The patients were given either 5 mg bromocriptine or placebo every day for 12 weeks and observed during the following 3 months. A biphasic basal body temperature curve and serum progesterone levels exceeding 25 nmol/l during the expected midluteal phase were considered an indication of ovulation. Restoration of ovulation was observed in 2 of 17 women given bromocriptine and 4 of 13 women given placebo. Bromocriptine was found to have no specific effect on the restoration of ovulation in women with secondary amenorrhea and normoprolactinemic normo-hypogonadotropic hypogonadism.
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D001971:Bromocriptine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D007031:Hypothalamus / Q000503:physiopathology; D010053:Ovary / Q000503:physiopathology; D010062:Ovulation Induction; D011388:Prolactin / Q000097:blood
D001971:Bromocriptine; D011388:Prolactin